

Docket: 28575/US/US


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	Rajinder Singh	
Application No.:	10/631,029	
Filing Date:	July 29, 2003	Examiner: Unknown
Title:	Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidendiamine Compounds	Group Art Unit: Unknown

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97(B)

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this document is being sent via First Class U.S. mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 5 day of JAN, 2004.

  
(Signature)


Dear Sir:


Pursuant to 37 CFR § 1.97(b), the references listed on the attached Form PTO-1449 (7 sheets, submitted in duplicate) are brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the identified references are enclosed as necessary. This IDS is being filed before the mailing of a first office action on the merits. In accordance with 37 CFR § 1.97(b), no statement or fee is required.

Respectfully submitted,

DORSEY & WHITNEY LLP  
Customer Number 25763

Date: January 5, 2004

By:   
Scott D. Rothenberger  
Reg. No. 41,277  
Intellectual Property Department  
Suite 1500  
50 South Sixth Street  
Minneapolis, MN 55402-1498  
(612) 340-8819



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/631,029
Filing Date	July 29, 2003
First Named Inventor	Rajinder Singh
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	28575/US/US

Sheet 1 of 7


**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 6,593,326	7/15/2003	Bradbury et al.	
		US- 6,579,983	6/17/2003	Batchelor	
		US- 6,528,513	3/4/2003	Cushing et al.	
		US- 6,525,051	2/25/2003	Davey et al.	
		US- 6,489,333	12/3/2002	Pitts et al.	
		US- 6,440,986	8/27/2002	Andries et al.	
		US- 6,432,963	8/13/2002	Hisamichi et al.	
		US- 6,372,751	4/16/2002	Davey et al.	
		US- 6,342,503	1/29/2002	Aldrich et al.	
		US- 6,337,335	1/8/2002	Hutchings et al.	
		US- 6,235,746	5/22/2001	Davis et al.	
		US- 6,200,977	3/13/2001	Cushing et al.	
		US- 6,197,779	3/6/2001	Andries et al.	
		US- 6,127,376	10/3/2000	Davey et al.	
		US- 6,080,858	6/27/2000	Schumacher	
		US- 6,048,866	4/11/2000	Hutchings et al.	
		US- 6,022,884	2/8/2000	Mantlo	
		US- 6,004,985	12/21/1999	Kochanny	
		US- 5,958,935	9/28/1999	Davis et al.	
		US- 5,863,924	1/26/1999	Berger et al.	
		US- 5,840,893	11/24/1998	Bukrinsky et al.	
		US- 5,585,381	12/17/1996	Yanaka et al.	
		US- 5,521,184	5/28/1996	Zimmermann	

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/631,029
Filing Date	July 29, 2003
First Named Inventor	Rajinder Singh
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	28575/US/US

Sheet

2

of

7

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 5,420,129	5/30/1995	Breu	
		US- 5,223,505	6/29/1993	Hargreaves	
		US- 5,179,204	1/12/1993	Effland et al.	
		US- 5,147,876	9/15/1992	Mizuchi et al.	
		US- 4,983,608	1/8/1991	Effland et al.	
		US- 3,159,547	12/1/1964	Hollis et al.	


**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
		WO	03/078404	9/25/2003	Novartis Pharma GmbH		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/074515	9/12/2003	Smithkline Beecham Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/066601	2/8/2002	Smithkline Beecham Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/062225	7/31/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/063794	8/7/2003	Rigel Pharmaceuticals Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/048133	6/12/2003	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/040141	5/15/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/032997	4/24/2003	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>	<input checked="" type="checkbox"/>
		WO	03/032994	4/24/2003	Boehringer Ingelheim Pharma KG		<input type="checkbox"/>	<input checked="" type="checkbox"/>
		WO	03/030909	4/17/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026666	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026665	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/026664	4/3/2003	Bayer Corporation		<input type="checkbox"/>	<input type="checkbox"/>
		WO	03/018022	3/6/2003	Amgen Inc.		<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/631,029
Filing Date	July 29, 2003
First Named Inventor	Rajinder Singh
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	28575/US/US

Sheet

3

of

7


**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		WO 03/018021	3/6/2003	Amgen Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 03/016306	2/27/2002	Janssen Pharmaceutica N.V.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 03/002544	1/9/2003	Bristol-Myers Squibb Company		<input type="checkbox"/>	<input type="checkbox"/>
		WO 03/000186	1/3/2003	Ariad Pharmaceuticals Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/102313	12/27/2002	Bristol-Myers Squibb Company		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/066481	8/29/2002	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/066480	8/29/2002	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/066461	8/28/2002	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/064096	8/22/2002	Tularik Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/062789	8/15/2002	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/059112	8/1/2002	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/059110	8/1/2002	Glaxo Group Limited		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/50066	6/27/2002	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/45652	6/13/2002	Merck & Co. Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/22601	3/21/1002	Vertex Pharmaceuticals, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 02/04429	1/17/2002	Astrazeneco AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO 01/85700	11/15/2001	Janssen Pharmaceutica N.V.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 01/85699	11/15/2001	Janssen Pharmaceutica N.V.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 01/72744	10/4/2001	Schering Aktiengesellschaft		<input type="checkbox"/>	<input type="checkbox"/>
		WO 01/64656	9/7/2001	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO 01/64654	9/7/2001	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>
		WO 01/64655	9/7/2001	Astrazeneca UK Limited		<input type="checkbox"/>	<input type="checkbox"/>
		WO 00/63182	4/20/1999	Bayer Aktiengesellschaft		<input type="checkbox"/>	<input checked="" type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/631,029
Filing Date	July 29, 2003
First Named Inventor	Rajinder Singh
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	28575/US/US

Sheet

4

of

7


**FOREIGN PATENT DOCUMENTS**

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION Yes No
		WO 01/60816	8/23/2001	Amgen Inc.		<input type="checkbox"/> <input type="checkbox"/>
		WO 01/23389	5//2001	Neuro-Gen Corporation		<input type="checkbox"/> <input type="checkbox"/>
		WO 01/22938	4/5/2001	Janssen Pharmaceutica N.V.		<input type="checkbox"/> <input type="checkbox"/>
		WO 01/09134	2/8/2001	Novartis AG		<input type="checkbox"/> <input type="checkbox"/>
		WO 00/76980	12/21/2000	Yamanouchi Pharmaceutical Co., Ltd.		<input type="checkbox"/> <input type="checkbox"/>
		WO 00/78731	12/28/2000	Cell-Tech Chiroscience Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO 00/39101	7/6/2000	Astrazeneca UK Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO 00/33844	6/15/2000	Berlex Laboratories Inc.		<input type="checkbox"/> <input type="checkbox"/>
		WO 00/27826	5/18/2000	Boehringer Ingelheim Pharma KG		<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 00/27825	5/18/2000	Janssen Pharmaceutica N.V.		<input type="checkbox"/> <input type="checkbox"/>
		WO 00/12485	3/9/2000	Zeneca Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO 99/61437	12/2/1999	Smithkline Beecham Corporation		<input type="checkbox"/> <input type="checkbox"/>
		WO 99/50251	10/7/1999	Cancer Research Campaign Technology Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO 99/50250	10/7/1999	Janssen Pharmaceutica N.V.		<input type="checkbox"/> <input type="checkbox"/>
		WO 99/50249	10/7/1999	Du Pont Pharmaceuticals Company		<input type="checkbox"/> <input type="checkbox"/>
		WO 99/41253	8/19/1999	Tularik Inc.		<input type="checkbox"/> <input type="checkbox"/>
		WO 99/31073	6/24/1999	Yamanouchi Pharmaceutical Co. Ltd.		<input type="checkbox"/> <input checked="" type="checkbox"/>
		WO 99/24874	5/20/1999	Zeneca Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO 98/41512	9/24/1998	Celltech Therapeutics Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO 97/19065	5/29/1997	Celltech Therapeutics Limited		<input type="checkbox"/> <input type="checkbox"/>
		WO 95/19358	7/20/1995	Sandoz-Patent GmbH		<input type="checkbox"/> <input type="checkbox"/>
		WO 91/18887	12/12/1991	Smith-Kline Beecham Intercredit B.V.		<input type="checkbox"/> <input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Information Disclosure Statement Form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Application Number</b> 10/631,029
				<b>Filing Date</b> July 29, 2003
				<b>First Named Inventor</b> Rajinder Singh
				<b>Art Unit</b> Unknown
				<b>Examiner Name</b> Unknown
<b>Sheet</b> 5	<b>of</b> 7	<b>Attorney Docket Number</b> 28575/US/US		

### FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION Yes No	
		WO 90/12790	11/1/1990	Imperial Chemical Industries PLC		<input type="checkbox"/>	<input type="checkbox"/>
		DE 4029650 A1	3/26/1992	Hoeschst AG		<input type="checkbox"/>	<input checked="" type="checkbox"/>
		AU 748087	8/30/1999	Tularik Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		EP 1 056 742 B1	12/6/2000	Tularik Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		EP 0525768	02/03/1993	J. Uriach & Cia. S.A.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 01/47897	07/05/2001	Pharmacopeia, Inc.		<input type="checkbox"/>	<input type="checkbox"/>
		WO 00/58305	10/05/2001	Astrazeneca UK Limited		<input type="checkbox"/>	<input type="checkbox"/>
		WO 03/076437	09/18/2003	Schering AG		<input type="checkbox"/>	<input type="checkbox"/>
		GB 2373186	09/18/2002	Astrazeneca AB		<input type="checkbox"/>	<input type="checkbox"/>


### OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION YES NO	
		Radinov et al., Fiziologheski Aktivnye Veshchestva 7:68-72 (1975)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
		Kuz'menko & Protsenko, Chemistry of Heterocyclic Compounds, pp. 105-107; English translation of Kuz'menko & Protsenko, Khimiya Geterotsiklicheskih Soedinenii 1:117-119 (1975)	<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(4-ethoxyphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0026	<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(2-methoxyphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0031	<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(4-methoxyphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1690-0003	<input type="checkbox"/>	<input type="checkbox"/>


EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/631,029	
				Filing Date	July 29, 2003	
				First Named Inventor	Rajinder Singh	
				Art Unit	Unknown	
				Examiner Name	Unknown	
Sheet	6	of	7	Attorney Docket Number	28575/US/US	
<b>OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS</b>						
		N2,N4-Bis(3-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0021			<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(2,5-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0024			<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(3,4-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0027			<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(4-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1690-0005			<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(2,4-dimethylphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0035			<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(3-bromophenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0059			<input type="checkbox"/>	<input type="checkbox"/>
		N2-(4-hydroxyphenyl)-N4-(4-methoxyphenyl)-6-methyl-2,4-diaminopyrimidine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1079-1249			<input type="checkbox"/>	<input type="checkbox"/>
		4-methyl-N-(4-t-butylphenyl)-6-(3,5-dimethylpyrazole)-2-pyrimidinamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #0122-0021			<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(4-hydroxy-2-methylphenyl)-6-methyl-5-nitro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #0781-2697			<input type="checkbox"/>	<input type="checkbox"/>
		6-(t-butyl)-2,4-pyrimidinediamine, commercially available from Maybridge, Cornwall, ENGLAND, catalog #GK 01685			<input type="checkbox"/>	<input type="checkbox"/>
		5-[(4-chlorophenyl)sulfonyl]-2,4-pyrimidinediamine, commercially available from Maybridge, Cornwall, ENGLAND, catalog #KM 00680			<input type="checkbox"/>	<input type="checkbox"/>
		6-(4-chlorophenyl)-2,4-pyrimidinediamine, commercially available from Maybridge, Cornwall, ENGLAND, catalog #GK 01237			<input type="checkbox"/>	<input type="checkbox"/>
EXAMINER SIGNATURE				DATE CONSIDERED		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						



Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<b>Application Number</b>	10/631,029
<b>Filing Date</b>	July 29, 2003
<b>First Named Inventor</b>	Rajinder Singh
<b>Art Unit</b>	Unknown
<b>Examiner Name</b>	Unknown
<b>Attorney Docket Number</b>	28575/US/US

Sheet

7

of

7

**OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
		N1-[2-amino-6-(4-fluoromethyl)pyrimidin-4-yl]-4-(trifluoromethyl)benzene-1-sulfonamide, commercially available from Maybridge, Cornwall, ENGLAND, catalog #GK 01714	<input type="checkbox"/>	<input type="checkbox"/>
		N4-(2,4-difluorophenyl)-6-methyl-2,4-pyrimidinediamine hydrochloride, commercially available from Maybridge, Cornwall, ENGLAND, catalog #RJF 00403	<input type="checkbox"/>	<input type="checkbox"/>
		N4-(3-pyridylmethyl)-6-methyl-2,4-pyrimadinediamine, commercially available from Maybridge, Cornwall, ENGLAND, catalog #RDR 02058		
		N4-[(3,4-dimethoxyphenyl)ethyl]-6-methyl-2,4-pyrimidinediamine, commercially available from Maybridge, Cornwall, ENGLAND, catalog #RDR 02059		
		N2,N4-Bisphenyl-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1142-0033	<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(3-methylphenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1690-0013	<input type="checkbox"/>	<input type="checkbox"/>
		N2,N4-Bis(2-chlorophenyl)-5-fluoro-2,4-pyrimidinediamine, commercially available from Contact Services/Chemdiv, San Diego, CA, catalog #1690-0007	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.